Summary
Mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) are associated with clinical responsiveness to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell lung cancers (NSCLCs). However, certain rare EGFR mutations including S768I are reported to confer less in-vitro sensitivity to gefitinib, an EGFR-TKI, than major mutations such as exon 19
deletions and L858R, and even the wild-type counterpart. Here, we report the first case of adenocarcinoma of the lung in which the patient had rare mutations S768I and V769L and was treated with gefitinib. Disease progressed during six weeks of treatment. This case suggests that in vitro sensitivity to gefitinib correlates with distinct clinical responsiveness to gefitinib in various types of EGFR mutations. Because of lower frequency of these novel mutations, clinical information of their relationships with drug responsiveness is very limited so far. We herein report a case of a patient with adenocarcinoma of the lung who exhibited two such rare mutations, S768I and V769L, and was treated with gefitinib.
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Case report
A 61-year-old male patient was admitted to our hospital in May 2005 after undergoing resection of a metastatic brain tumor from lung adenocarcinoma. He was a current heavy smoker who had 70 pack-year of smoking index. His chest CT scan revealed a 36-mm nodule in the right S 1 with multiple miliary metastasis in both lung fields (Fig. 1a,b) . He also exhibited contralateral mediastinal lymphadenopathy, bilateral adrenal gland metastasis, and sacroiliac joint metastasis. His disease was accordingly staged as cT4N3M1, stage IV. Thrombocytopenia was also evident (platelet count < 100,000 / ul) and bone marrow aspiration revealed myelodysplastic syndrome. Taking the patient's general condition and opinion into account, we offered him gefitinib treatment at an oral dose of 250 mg daily as first-line therapy.
The nine-week Gefitinib administration period included a three-week interruption, during which the patient underwent radiation therapy for residual brain tumor. However, despite over six weeks of gefitinib administration, chest and abdominal CT revealed enlargement of the primary lesion and pulmonary and adrenal metastases. These lesions were therefore thought to be resistant to gefitinib and the response was evaluated as progressive disease according to the RECIST criteria (Fig. 1c,d) (Fig. 3) .
Discussion
To the best of our knowledge, this is the first reported case of a patient with the rare mutations S768I and V769L treated with gefitinib.
The relationship between EGFR mutations and sensitivity to EGFR-TKI in NSCLCs remains controversial. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] 13 Although multiple studies have shown striking correlation between these factors, 4 (demonstrating S768I and V769L). However, the clinical responsiveness of EGFR-TKIs to these mutations has not been shown.
In in-vitro studies, various mutations were shown to have the distinctive phosphorylation patterns of several C-terminal Tyrosine (Tyr) residues of EGFR and different sensitivities to gefitinib when they were stably transfected to a NSCLC cell line. 11, 14 Some of these mutations, including S768I, are hyperphosphorylated on the Tyr 1045 residue, which is known to recruit Cbl to EGFR and to lead to Cbl-mediated receptor multi-ubiquitination, and are refractory to EGF-induced ubiquitination and degradation. [15] [16] [17] mutations. Although HER2 mutations in lung cancer are rare, they have also been reported to be associated with the resistance to another EGFR-TKI, Erlotinib. 19 Heterogeneity of the tumor might also affect the clinical response, since his mutational analysis was done using a surgical sample from one of the metastatic sites. 
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